431 related articles for article (PubMed ID: 27149298)
41. Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls.
Li J; Knoll S; Bocharova I; Tang W; Signorovitch J
Curr Med Res Opin; 2019 Jan; 35(1):105-111. PubMed ID: 30362839
[No Abstract] [Full Text] [Related]
42. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
[TBL] [Abstract][Full Text] [Related]
43. Clinical Efficacy of Alectinib in Patients with
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
[TBL] [Abstract][Full Text] [Related]
44. Ceritinib Outperforms Chemo as Second-Line Treatment.
Cancer Discov; 2016 Dec; 6(12):OF5. PubMed ID: 27780805
[TBL] [Abstract][Full Text] [Related]
45. Successful treatment with ceritinib after crizotinib induced hepatitis.
Sassier M; Mennecier B; Gschwend A; Rein M; Coquerel A; Humbert X; Alexandre J; Fedrizzi S; Gervais R
Lung Cancer; 2016 May; 95():15-6. PubMed ID: 27040846
[TBL] [Abstract][Full Text] [Related]
46. Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
Vansteenkiste JF
Future Oncol; 2014 Oct; 10(12):1925-39. PubMed ID: 24856155
[TBL] [Abstract][Full Text] [Related]
47. Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.
Facchinetti F; Caramella C; Auger N; Planchard D; Adam J; Lacroix L; Remon J; Massard C; Soria JC; Friboulet L; Besse B
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27197808
[TBL] [Abstract][Full Text] [Related]
48. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
Califano R; Greystoke A; Lal R; Thompson J; Popat S
Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
[TBL] [Abstract][Full Text] [Related]
49. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
[TBL] [Abstract][Full Text] [Related]
50. [Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer].
Giroux Leprieur E; Fallet V; Wislez M
Bull Cancer; 2015 Dec; 102(12):1053-7. PubMed ID: 26597476
[TBL] [Abstract][Full Text] [Related]
51. Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer.
Cooper MR; Chim H; Chan H; Durand C
Ann Pharmacother; 2015 Jan; 49(1):107-12. PubMed ID: 25258420
[TBL] [Abstract][Full Text] [Related]
52. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
53. Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
Landi L; Cappuzzo F
Expert Rev Clin Pharmacol; 2016; 9(2):203-14. PubMed ID: 26582431
[TBL] [Abstract][Full Text] [Related]
54. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.
Reckamp K; Lin HM; Huang J; Proskorovsky I; Reichmann W; Krotneva S; Kerstein D; Huang H; Lee J
Curr Med Res Opin; 2019 Apr; 35(4):569-576. PubMed ID: 30286627
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
56. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Toyokawa G; Seto T; Takenoyama M; Ichinose Y
Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
[TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.
Sivignon M; Monnier R; Tehard B; Roze S
PLoS One; 2020; 15(1):e0226196. PubMed ID: 31945065
[TBL] [Abstract][Full Text] [Related]
58. Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.
Carlson JJ; Suh K; Orfanos P; Wong W
Pharmacoeconomics; 2018 Apr; 36(4):495-504. PubMed ID: 29488070
[TBL] [Abstract][Full Text] [Related]
59. Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China.
Huang M; Tian Y; He M; Liu J; Ren L; Gong Y; Peng F; Wang Y; Ding Z; Wang J; Zhu J; Xu Y; Liu Y; Li L; Lu Y
J Comp Eff Res; 2020 Jan; 9(2):93-102. PubMed ID: 31958984
[No Abstract] [Full Text] [Related]
60. Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report.
Zhu Z; Chai Y
Medicine (Baltimore); 2017 Nov; 96(45):e8652. PubMed ID: 29137103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]